140 related articles for article (PubMed ID: 3944748)
41. Interleukin-1 receptor antagonist in differential diagnosis of inflammatory bowel diseases.
Propst A; Propst T; Herold M; Vogel W; Judmaier G
Eur J Gastroenterol Hepatol; 1995 Nov; 7(11):1031-6. PubMed ID: 8680901
[TBL] [Abstract][Full Text] [Related]
42. Diagnostic value of serum procalcitonin in determining the activity of inflammatory bowel disease.
Oruç N; Ozütemiz O; Osmanoğlu N; Ilter T
Turk J Gastroenterol; 2009 Mar; 20(1):9-12. PubMed ID: 19330729
[TBL] [Abstract][Full Text] [Related]
43. Soluble urokinase plasminogen activator receptor suPAR as a marker for inflammation in pediatric inflammatory bowel disease.
Kolho KL; Valtonen E; Rintamäki H; Savilahti E
Scand J Gastroenterol; 2012 Sep; 47(8-9):951-5. PubMed ID: 22746351
[TBL] [Abstract][Full Text] [Related]
44. The disease activity of ulcerative colitis and Crohn's disease.
Talstad I; Gjone E
Scand J Gastroenterol; 1976; 11(4):403-8. PubMed ID: 935802
[TBL] [Abstract][Full Text] [Related]
45. Correlation of C-reactive protein with clinical, endoscopic, histologic, and radiographic activity in inflammatory bowel disease.
Solem CA; Loftus EV; Tremaine WJ; Harmsen WS; Zinsmeister AR; Sandborn WJ
Inflamm Bowel Dis; 2005 Aug; 11(8):707-12. PubMed ID: 16043984
[TBL] [Abstract][Full Text] [Related]
46. [Neopterin in assessing the activity of inflammatory bowel diseases: ulcerative colitis and Crohn's disease].
Ciećko-Michalska I; Fedak D; Mach T
Przegl Lek; 2010; 67(12):1262-5. PubMed ID: 21591350
[TBL] [Abstract][Full Text] [Related]
47. Performance of blood tests in diagnosis of inflammatory bowel disease in a specialist clinic.
Cabrera-Abreu JC; Davies P; Matek Z; Murphy MS
Arch Dis Child; 2004 Jan; 89(1):69-71. PubMed ID: 14709513
[TBL] [Abstract][Full Text] [Related]
48. Efficacy of noninvasive evaluations in monitoring inflammatory bowel disease activity: A prospective study in China.
Chen JM; Liu T; Gao S; Tong XD; Deng FH; Nie B
World J Gastroenterol; 2017 Dec; 23(46):8235-8247. PubMed ID: 29290660
[TBL] [Abstract][Full Text] [Related]
49. Correlations between clinical activity, endoscopic severity, and biological parameters in colonic or ileocolonic Crohn's disease. A prospective multicentre study of 121 cases. The Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives.
Cellier C; Sahmoud T; Froguel E; Adenis A; Belaiche J; Bretagne JF; Florent C; Bouvry M; Mary JY; Modigliani R
Gut; 1994 Feb; 35(2):231-5. PubMed ID: 7508411
[TBL] [Abstract][Full Text] [Related]
50. Biological measurements of Crohn's disease activity--a reassessment.
André C; Descos L; André F; Vignal J; Landais P; Fermanian J
Hepatogastroenterology; 1985 Jun; 32(3):135-7. PubMed ID: 2410345
[TBL] [Abstract][Full Text] [Related]
51. Markers of coagulation and fibrinolysis as measures of disease activity in inflammatory bowel disease.
Kjeldsen J; Lassen JF; Brandslund I; Schaffalitzky de Muckadell OB
Scand J Gastroenterol; 1998 Jun; 33(6):637-43. PubMed ID: 9669637
[TBL] [Abstract][Full Text] [Related]
52. The insulin-like growth factor (IGF)-system in active ulcerative colitis and Crohn's disease: relations to disease activity and corticosteroid treatment.
Eivindson M; Grønbaek H; Flyvbjerg A; Frystyk J; Zimmermann-Nielsen E; Dahlerup JF
Growth Horm IGF Res; 2007 Feb; 17(1):33-40. PubMed ID: 17126585
[TBL] [Abstract][Full Text] [Related]
53. Comparison of serum total sialic acid, C-reactive protein, alpha 1-acid glycoprotein and beta 2-microglobulin in patients with non-malignant bowel diseases.
Ricci G; D'Ambrosi A; Resca D; Masotti M; Alvisi V
Biomed Pharmacother; 1995; 49(5):259-62. PubMed ID: 7579005
[TBL] [Abstract][Full Text] [Related]
54. Some serum protein studies in Crohn's disease and ulcerative colitis.
Sandor G; Levy E; Malafosse M; Huguet C; Huguier M; Loygue J
Res Commun Chem Pathol Pharmacol; 1975 May; 11(1):129-45. PubMed ID: 1153856
[TBL] [Abstract][Full Text] [Related]
55. The insulin-like growth factor system and markers of inflammation in adult patients with inflammatory bowel disease.
Eivindson M; Nielsen JN; Grønbaek H; Flyvbjerg A; Hey H
Horm Res; 2005; 64(1):9-15. PubMed ID: 16088202
[TBL] [Abstract][Full Text] [Related]
56. Serum neutrophil gelatinase-associated lipocalin (NGAL) correlates with clinical and endoscopic activity in ulcerative colitis but fails to predict activity in Crohn's disease.
Budzynska A; Gawron-Kiszka M; Nowakowska-Dulawa E; Spiewak J; Lesinska M; Kukla M; Waluga M; Hartleb M
J Physiol Pharmacol; 2017 Dec; 68(6):859-865. PubMed ID: 29550798
[TBL] [Abstract][Full Text] [Related]
57. Enteric protein loss measured by fecal alpha 1-antitrypsin clearance in the assessment of Crohn's disease activity: a study of children and adolescents.
Griffiths AM; Drobnies A; Soldin SJ; Hamilton JR
J Pediatr Gastroenterol Nutr; 1986; 5(6):907-11. PubMed ID: 3491890
[TBL] [Abstract][Full Text] [Related]
58. Correlations of plasma citrulline levels with clinical and endoscopic score and blood markers according to small bowel involvement in pediatric Crohn disease.
Lee EH; Ko JS; Seo JK
J Pediatr Gastroenterol Nutr; 2013 Nov; 57(5):570-5. PubMed ID: 23752073
[TBL] [Abstract][Full Text] [Related]
59. [Comparison of the indexes of serologic activity with endoscopy in intestinal inflammatory disease].
Martínez Salmerón JF; Rodrigo M; Nogueras F; de Sola C; Corral C; Ortega C; Martín-Vivaldi R
Gastroenterol Hepatol; 1996; 19(7):344-6. PubMed ID: 8963902
[TBL] [Abstract][Full Text] [Related]
60. Serum lysozyme in inflammatory bowel disease.
Nugent FW; Mallari R; George H; Ridley N
Gastroenterology; 1976 Jun; 70(6):1014-6. PubMed ID: 1269861
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
